Trials / Completed
CompletedNCT01145313
Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 501 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to examine changes in pre/post-augmentation healthcare costs and resource utilization in patients diagnosed with major depressive disorder (MDD) who augment their current antidepressant therapy with an atypical antipsychotic.
Conditions
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2010-06-16
- Last updated
- 2013-11-08
Source: ClinicalTrials.gov record NCT01145313. Inclusion in this directory is not an endorsement.